Remembering seasonal coronaviruses

Antibodies against seasonal coronaviruses react with SARS-CoV-2

Sarscov2, Sciencemagarchives

1/26/2022 11:30:00 PM

Remembering seasonal coronaviruses: Two 2020 studies in Science revealed that individuals exposed and unexposed to SARSCoV2 have cross-reactive serum antibodies against the spike protein of SARS-CoV-2 and seasonal human coronaviruses. ScienceMagArchives

Antibodies against seasonal coronaviruses react with SARS-CoV-2

) reveal that individuals exposed and unexposed to SARS-CoV-2 have cross-reactive serum antibodies against the spike protein of SARS-CoV-2 and seasonal HCoVs.Four seasonal HCoV strains cause cold symptoms in humans: 229E, NL63, OC43, and HKU1. Despite using different host receptors for cellular entry, all HCoVs express the spike protein on their surface. The spike protein is composed of two subunits: S1 contains the receptor-binding domain (RBD), which is responsible for binding to host cell receptors, and S2 is critical for mediating viral and host cell membrane fusion and cell entry. The fusion peptide of the S2 subunit is highly conserved among seasonal HCoVs and zoonotic coronaviruses, including SARS-CoV-2 (

Read more: Science Magazine »

If climate change is making heat waves 100 times more likely in India, this is who will suffer most

As scientists warn heat waves are 100 times more likely in the region, millions of workers can't afford to take a day off, even if the heat could kill them. Read more >>

Ok New let’s see when the zero covid brigade storms here and declare these studies denialist hopium, ”sars-cov-2 is COMPLETELY different, defying everything we know about immunology”. Lyers Ok finally

SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodiesA study of antibodies from SARSCoV2 Beta variant-infected patients revealed that while some antibodies bind both Beta & wild-type virus, others are Beta-specific. The results emphasize the antigenic complexity defining antibody immunity against SARS-CoV-2

Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagementThe SARS-CoV-2 Omicron variant of concern evades antibody-mediated immunity that comes from vaccination or infection with earlier variants due to accumulation of numerous spike mutations. To understand the Omicron antigenic shift, we determined cryo-... Link doesn't work 😕 That link is broken but I think it meant to point to this article: That's a great find! Just the kind of information the rest of the world needs!!!

SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters - NatureNature - <ArticleTitle Language="En" xml:lang="en">SARS-CoV-2 Omicron virus causes attenuated disease in mice and...

Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responsesPreclinical experiments in human cells and mice suggest CBD may prevent the replication of SARSCoV2, but the authors advise caution until completion of a clinical trial, citing questions on dosage, formulation, and mode of delivery. ScienceAdvances ScienceAdvances so the bxo1 inhibits that rna molecule of that cbd compost, wow amazing. i dont know what i justsaid. ScienceAdvances concept as a bronchial dialator response specific to the interaction given by CBD...it makes sense to follow the line of reason to the familys of fir needle as a compound..Fir Temporal range: Eocene - Present Family:Pinaceae Subfamily:Abietoideae Genus:Abies Mill. Type species ScienceAdvances May pharma not going to be a get gate keeper

Covid-19 news: Strain on health services led to extra non-covid deathsToday’s covid-19 news: · 4000 excess non-covid 19 deaths occurred in England during first year of pandemic · Acute phase of pandemic could end in 2022 with improved vaccination rates, says WHO · Israel recommends fourth vaccine dose for all adults The most deadly pandemic in US, Abortion 2017 =862,000 US goes crazy with covid deaths =650,000 You know who else spread fake news? Adolf Hitler “tell a big enough lie and tell it frequently enough, it will be believed.”

Covid-19 news: Infections in England remain at ‘extremely high’ levelToday’s covid-19 news: · Infections in England remain at very high levels as cases rise in children · 98 per cent of UK adults have antibodies to virus that causes covid-19 · Two studies identify markers that may predict long covid

4 ) reveal that individuals exposed and unexposed to SARS-CoV-2 have cross-reactive serum antibodies against the spike protein of SARS-CoV-2 and seasonal HCoVs. Four seasonal HCoV strains cause cold symptoms in humans: 229E, NL63, OC43, and HKU1. Despite using different host receptors for cellular entry, all HCoVs express the spike protein on their surface. The spike protein is composed of two subunits: S1 contains the receptor-binding domain (RBD), which is responsible for binding to host cell receptors, and S2 is critical for mediating viral and host cell membrane fusion and cell entry. The fusion peptide of the S2 subunit is highly conserved among seasonal HCoVs and zoonotic coronaviruses, including SARS-CoV-2 ( ), whereas S1 is more variable. Shrock et al. found that people unexposed to SARS-CoV-2 have cross-reactive antibody responses against an array of coronaviruses, including the recently emerged SARS-CoV-2. However, most of this preexisting immunity targets a few epitopes on the spike protein, nucleocapsid protein, and the nonstructural proteins that are encoded by open reading frame 1. Using a sensitive flow cytometric assay to detect cross-reactive serum antibodies, Ng et al. found that individuals unexposed to SARS-CoV-2 possessed neutralizing antibodies against the S2 protein. Cross-reactive antibodies were class-switched to the mature antibody isotypes immunoglobulin G (IgG) and IgA, suggesting that B cells producing these cross-reactive antibodies were induced by a previous immune response against infection with seasonal HCoVs. Upon SARS-CoV-2 infection, individuals showed increased production of antibodies that cross-react with the spike proteins of SARS-CoV-2 and seasonal HCoVs, called back-boosting (see the figure). Back-boosting is a common phenomenon observed after influenza virus infection and vaccination that results in the recall of antibodies targeting conserved epitopes of past circulating influenza viruses ( 5 ). Back-boosting can be directed to nonprotective epitopes, such as those on the unexposed nucleocapsid protein, which is referred to as original antigenic sin. However, back-boosting can lead to the recall of broadly neutralizing antibodies, as observed with the 2009 pandemic H1N1 influenza virus (